Metabasis Therapeutics study shows CS-917 has potential to lower blood glucose

By Lisa Kerner

Charlotte, N.C., June 12 - Metabasis Therapeutics, Inc. made four poster presentations and discussed two publications relative to its first-in-class oral product candidate CS-917 at the American Diabetes Association meeting.

CS-917, discovered by Metabasis using its proprietary NuMimetic technology, is being studied in a phase 2b human clinical trial for type 2 diabetes. Metabasis is developing CS-917 in partnership with Daiichi Sankyo.

"The study presented at the ADA entailed evaluation of several doses of CS-917 versus placebo given once a day for 14 days to patients with type 2 diabetes," president Paul Laikind said in a company news release.

"This study demonstrated the potential for CS-917 to lower blood glucose."

Metabasis is a San Diego-based biopharmaceutical company developing novel drugs to treat metabolic and liver diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.